Plea for multitargeted interventions for severe COVID-19.
作者信息
Gaborit Benjamin Jean, Bergmann Jean-François, Mussini Cristina, Arribas Jose Ramon, Behrens Georg, Walmsley Sharon, Pozniak Anton, Raffi François
机构信息
Department of Infectious Diseases, Hotel-Dieu Hospital and INSERM CIC 1413, Nantes University Hospital, Nantes 44093, France.
Internal Medicine Department, Lariboisière Hospital, Paris, France.
出版信息
Lancet Infect Dis. 2020 Oct;20(10):1122-1123. doi: 10.1016/S1473-3099(20)30312-1. Epub 2020 Apr 21.
Abstract
摘要
相似文献
1
Plea for multitargeted interventions for severe COVID-19.呼吁对重症 COVID-19 采取多靶点干预措施。
Lancet Infect Dis. 2020 Oct;20(10):1122-1123. doi: 10.1016/S1473-3099(20)30312-1. Epub 2020 Apr 21.
2
Curing COVID-19.治愈新冠病毒肺炎
Lancet Infect Dis. 2020 Oct;20(10):1101. doi: 10.1016/S1473-3099(20)30706-4. Epub 2020 Sep 10.
3
Treatments for COVID-19: where are we now?2019冠状病毒病的治疗方法：我们目前处于什么阶段？
Br J Community Nurs. 2020 Aug 2;25(8):412-413. doi: 10.12968/bjcn.2020.25.8.412.
4
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.2019新型冠状病毒治疗的治疗选择：循证方法
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
5
Oxytocin as a potential defence against Covid-19?催产素能否成为对抗新冠病毒的潜在防御手段？
Med Hypotheses. 2020 Jul;140:109785. doi: 10.1016/j.mehy.2020.109785. Epub 2020 Apr 23.
6
Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?多发性硬化症中干扰素-β的三十年：我们能否将这些信息用于治疗新型冠状病毒2感染？
Front Immunol. 2020 Jun 18;11:1459. doi: 10.3389/fimmu.2020.01459. eCollection 2020.
7
Purposing Saikosaponins for the treatment of COVID-19.将柴胡皂苷用于治疗新型冠状病毒肺炎。
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
8
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.新型冠状病毒肺炎（COVID-19）大流行期间重症肌无力（MG）和兰伯特-伊顿肌无力综合征（LEMS）的管理指南。
J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.
9
Hydroxychloroquine in Covid-19: Does the end justify the means?新冠疫情中使用羟氯喹：结果能证明手段合理吗？
Curr Res Transl Med. 2020 Aug;68(3):81-82. doi: 10.1016/j.retram.2020.04.002. Epub 2020 Apr 18.
10
World War against COVID-19: How strong is our armamentarium?抗击新冠疫情之战：我们的武器库有多强大？
Med J Malaysia. 2020 May;75(3):314-315.
引用本文的文献
1
SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.严重急性呼吸综合征冠状病毒 2 型、寨卡病毒和支原体：这些新发病毒性和细菌性传染病的结构、发病机制及一些治疗选择。
Biochim Biophys Acta Mol Basis Dis. 2021 Dec 1;1867(12):166264. doi: 10.1016/j.bbadis.2021.166264. Epub 2021 Sep 3.
2
Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update.新型冠状病毒肺炎间充质干细胞治疗的特点与进展：最新综述
Stem Cells Int. 2021 Jun 2;2021:5593584. doi: 10.1155/2021/5593584. eCollection 2021.
3
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.XAV-19，一种猪源人源化多克隆抗 SARS-CoV-2 抗体用于治疗 COVID-19 相关中度肺炎的药代动力学和安全性：一项随机、双盲、安慰剂对照、IIa 期研究。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0123721. doi: 10.1128/AAC.01237-21.
4
COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.新型冠状病毒肺炎：感染期间多个系统失衡和心脏及抗凝治疗选择及剂量的重要性。
Mol Biol Rep. 2021 Mar;48(3):2917-2928. doi: 10.1007/s11033-021-06333-w. Epub 2021 Apr 10.
5
Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.间充质干细胞衍生的细胞外囊泡携带 miRNA 作为 COVID-19 的潜在多靶点治疗方法：一项计算机分析。
Stem Cell Rev Rep. 2021 Apr;17(2):341-356. doi: 10.1007/s12015-021-10122-0. Epub 2021 Jan 28.
6
Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future.非洲对新型冠状病毒（COVID-19）大流行的应对：成就、挑战及对未来的影响
Front Pharmacol. 2020 Sep 11;11:1205. doi: 10.3389/fphar.2020.01205. eCollection 2020.
7
Projected supportive effects of Pycnogenol in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection.预计碧萝芷对感染 SARS-CoV2 后多维健康受损的患者有辅助作用。
Int J Antimicrob Agents. 2020 Dec;56(6):106191. doi: 10.1016/j.ijantimicag.2020.106191. Epub 2020 Oct 9.
8
Preemptive interleukin-6 blockade in patients with COVID-19.COVID-19 患者的预防性白细胞介素 6 阻断。
Sci Rep. 2020 Oct 8;10(1):16826. doi: 10.1038/s41598-020-74001-3.
9
Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.靶向 SphK-S1P-SIPR 通路作为 COVID-19 的一种潜在治疗方法。
Int J Mol Sci. 2020 Sep 29;21(19):7189. doi: 10.3390/ijms21197189.
10
Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19?基于细胞外囊泡治疗肺损伤的系统评价：细胞外囊泡是治疗新型冠状病毒肺炎的潜在疗法吗？
J Extracell Vesicles. 2020 Aug 6;9(1):1795365. doi: 10.1080/20013078.2020.1795365.
本文引用的文献
1
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
4
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
5
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.致病性人类冠状病毒感染：细胞因子风暴和免疫病理学的成因及后果
Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2.
Zotero 插件